Tag: nerves

HealthpointCapital Acquires ImmersiveTouch, Inc., a Leading Extended Reality Surgical Platform

SAN DIEGO and CHICAGO, June 30, 2025 /PRNewswire/ -- HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

£7.5 million Longitude Prize on ALS launches

LONDON, June 25, 2025 /CNW/ -- The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to incentivise and reward cutting...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies¹, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug developmentAppointments...

Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapies | DelveInsight

The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L...

Steve Jobs Talked Pretty — So What?

In June 2005, Steve Jobs was roped into delivering a commencement speech at Stanford. He wasn't thrilled, calling it "embarrassing" in an email to...

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

The multiple sclerosis market is growing due to rising prevalence, earlier diagnosis, and wider access to care. Demand is fueled by advancements in DMTs...

Friedreich’s Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new...

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan

Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus Plan

Alvopetro Announces June 2025 Sales Volumes

Oxford Business Group and Oman Investment Authority highlight sultanate’s economic transformation in new advisory report

MTY Food Group Inc Will Hold a Conference Call to Discuss Its Second Quarter Results

Tag: nerves

HealthpointCapital Acquires ImmersiveTouch, Inc., a Leading Extended Reality Surgical Platform

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

£7.5 million Longitude Prize on ALS launches

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

Chronic Lower Back Pain Market to Expand Significantly During the Forecast Period (2025-2034) with Game-Changing Therapies | DelveInsight

Steve Jobs Talked Pretty — So What?

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight

Friedreich’s Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us